EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. - Wikidata - awgldk - TriplyDB

EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

http://www.wikidata.org/entity/Q38169849

about

Androgen-targeted therapy-induced epithelial mesenchymal plasticity and neuroendocrine transdifferentiation in prostate cancer: an opportunity for intervention Gynecomastia in Patients with Prostate Cancer: A Systematic Review Exposure to bisphenol A correlates with early-onset prostate cancer and promotes centrosome amplification and anchorage-independent growth in vitro Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer Evidence-based recommendations on androgen deprivation therapy for localized and advanced prostate cancer Splice Variants of Androgen Receptor and Prostate Cancer Advances in genetics: widening our understanding of prostate cancer A Perspective of Immunotherapy for Prostate Cancer Role of Dose Intensification for Salvage Radiation Therapy after Radical Prostatectomy Surgery and hormonal treatment for prostate cancer and sexual function Adaptive responses of androgen receptor signaling in castration-resistant prostate cancer Multiparametric magnetic resonance imaging for prostate cancer: A review and update for urologists A comprehensive review of contemporary role of local treatment of the primary tumor and/or the metastases in metastatic prostate cancer Health Economics and Radium-223 (Xofigo®) in the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Case History and a Systematic Review of the Literature Hormone naïve prostate cancer: predicting and maximizing response intervals Salvage local therapy for radiation-recurrent prostate cancer - where are we?Urethral strictures after radiation therapy for prostate cancer Androgen deprivation therapy as backbone therapy in the management of prostate cancer Epigenetic modulators as therapeutic targets in prostate cancer Target Definition in Salvage Radiotherapy for Recurrent Prostate Cancer: The Role of Advanced Molecular Imaging Oligometastatic Prostate Cancer A review of clinical effects associated with metabolic syndrome and exercise in prostate cancer patients Updates of prostate cancer staging: Prostate-specific membrane antigen Comparison of Robot-Assisted Radical Prostatectomy and Open Radical Prostatectomy Outcomes: A Systematic Review and Meta-Analysis Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis Advances in hormonal therapies for hormone naïve and castration-resistant prostate cancers with or without previous chemotherapy Nanoparticles as Theranostic Vehicles in Experimental and Clinical Applications-Focus on Prostate and Breast Cancer.Variation in the use of postoperative radiotherapy among high-risk patients following radical prostatectomy.Safety and efficacy of 2-weekly cabazitaxel in metastatic castration-resistant prostate cancer.Robot-assisted radical prostatectomy has lower biochemical recurrence than laparoscopic radical prostatectomy: Systematic review and meta-analysis.Comparing the rules of engagement of androgen and glucocorticoid receptors Conversion to monotherapy with luteinizing-hormone releasing hormone agonist or orchiectomy after reaching PSA nadir following maximal androgen blockade is able to prolong progression-free survival in patients with metastatic prostate cancer: A prop Incremental diagnostic utility of systematic double-bed SPECT/CT for bone scintigraphy in initial staging of cancer patients.Characteristics of prostate cancer detection rate (PCDR) in Chinese Han population under different prostate biopsy methods.Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence Neuropilin-1 is upregulated in the adaptive response of prostate tumors to androgen-targeted therapies and is prognostic of metastatic progression and patient mortality.Abiraterone for castration-resistant prostate cancer: adherence, survival and hospitalization : Analysis of a medical claims database.Androgen deprivation therapy for prostate cancer: long-term safety and patient outcomes Prostate-specific membrane antigen positron emission tomography in prostate cancer: a step toward personalized medicine.Low-frequency ultrasound-induced VEGF suppression and synergy with dendritic cell-mediated anti-tumor immunity in murine prostate cancer cells in vitro.

P2860

Q21129293-FE49DB7C-9AA6-4257-9200-B3B8A8B4B1F7 Q21131717-60A9D956-73A8-4F9C-866C-190B20D50F9A Q21132302-6C735813-730D-4D8C-8F1D-E710A159FDAE Q26739708-0886137E-58F2-4886-99EB-8AA2672C329F Q26739738-39768F0E-AA60-440A-B1AB-D4EF8739D159 Q26740592-31ED0D52-29F7-4408-91C0-3A9704B3425C Q26740628-CB769D02-7C95-403E-9C93-6378B39BDE3F Q26741277-6F8CFB7B-B53D-46FF-963F-EA3C8B3AF2A9 Q26765872-61DFA955-4120-412F-AA40-F04C7A16AA76 Q26773774-2CB885BA-6073-4BDF-9A63-55B62A928495 Q26795625-11724895-E3EA-4248-AC19-119827549B74 Q26801576-AC105B31-878F-41FC-A4B5-E8D1CFAAEE40 Q27000180-5FA08ED3-FF77-43CB-8193-039890A5598E Q27004566-43A76672-B4A1-4D5F-8557-E45393A38321 Q27015904-4E0821FA-0011-4F15-BA50-EBC469611E5F Q28065991-4CDEAD30-6925-49FB-9689-D9F5BFABB692 Q28067904-4FFF423D-3191-471B-B7A7-9DB9998F12F0 Q28071795-F9FD45F3-47B0-47F8-AD6E-36B8BEE6612B Q28071912-4A1B2A14-42D1-4706-ACCA-D0B735F99423 Q28074669-842DC774-8166-4F5F-879A-780B0283C05A Q28075182-35401573-D969-43ED-A09D-ECDFEF3366DC Q28076622-8DF9099A-622C-4EC9-B74E-9A4F5822753E Q28079444-85E8A6A8-758E-469D-8EAD-C907BB3EB117 Q28079747-D17B76D9-4F32-480E-9E0B-4D24E42C676B Q28550301-25A113F7-AA29-408A-B52C-42A6077FFAF2 Q28829239-E5AEECF5-2252-4DA0-8945-6C8BD7675DD7 Q30354652-3F2F81C9-EBDA-4C53-AC5D-AAEBA337F6B4 Q30385364-D3F3CD94-5AB4-4BFE-98DB-675AD730ACDC Q33440646-8F91E2E4-96C6-4465-AF9D-D0E88F2312A0 Q33641989-72437DC1-CF88-41CA-A28F-62426F7FC392 Q33658855-4CED54ED-3EFE-44AE-8E68-1426588FCA8E Q33750752-B08FA6AF-E67D-4D37-9969-AF12A00EDFB5 Q33776371-A4D42B27-C15F-4F66-81F8-F2CF4B6CAF80 Q33779314-0DFF98D3-8D0D-4444-8F42-F6BF504CDCE3 Q33789117-12DF1BB3-2B7D-4F20-A05B-837F8086F304 Q33835918-F0DC7575-A89D-4DBC-B745-EE4436D5D683 Q33841309-0E12F441-2222-4635-B63D-C08C52979270 Q33890406-CB11FE7F-BA8C-470F-8630-93B3319AF9EA Q33914844-B2070EE7-193D-443A-8644-C89AFACEAA66 Q33915914-B8DE4CF0-FA99-4039-8735-3C923BB582BC

P2860

EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

http://www.wikidata.org/entity/Q38169849

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh

2013年學術文章

@zh-hant

name

EAU guidelines on prostate can ...... ion-resistant prostate cancer.

@en

type

label

EAU guidelines on prostate can ...... ion-resistant prostate cancer.

@en

prefLabel

EAU guidelines on prostate can ...... ion-resistant prostate cancer.

@en

P1433

Q38169849-CB368AA2-0863-4A4B-BD11-17E3D8F6A2DA

P1476

Q38169849-126491C8-F202-449B-BD73-8C20D5C49EB1

P2093

Q38169849-17DA0FED-B04D-4515-ADAE-604F581C0364

Q38169849-349048D8-AD67-407D-9D4F-6AA3DD9C3320

Q38169849-705E8DE8-3510-4B49-8A82-7DBA36EAE681

Q38169849-7919959A-54E3-4321-AFD6-BE33E0D46002

Q38169849-9605ADE3-E9C7-4A86-A51C-60C5DB79B1D5

Q38169849-96AF89E3-1B00-4A14-8240-E030CFC4F10D

Q38169849-C20818D9-D042-4718-86E9-9AB14DA23E6B

Q38169849-C816208D-5E32-4E38-9A62-4AFA1B9B3A49

Q38169849-DCAAD6CB-2482-4CE4-A9F6-21AB74C09CE1

Q38169849-DE754192-4FA7-4D6B-B93C-75C1A3E529F4

P304

Q38169849-88AC7B6A-0C70-4590-9E22-6B71290FECA3

P31

Q38169849-56857C51-DAED-4713-9D56-D572D8B5C3A4

P356

Q38169849-003487C2-756D-4DB5-8251-588D35FACC36

P407

Q38169849-4C23C0CA-E5F7-41DE-B30F-D9D3C45DB5B3

P433

Q38169849-9E8A1E00-5EFB-45A8-839D-82D819A8C26E

P478

Q38169849-08A20E23-D96A-4C8E-8076-C2DE92142728

P50

Q38169849-2AFDA671-5DF3-4EB7-89ED-695E72871E27

Q38169849-2DEB8743-C651-4270-AE6C-62DEA9C13351

P577

Q38169849-34EE3FED-5534-403C-B281-21C142CD00FC

P698

Q38169849-4009AA90-D045-442F-AA61-6034906D625B

P356

J.EURURO.2013.11.002

P1433

European Urology

P1476

EAU guidelines on prostate can ...... tion-resistant prostate cancer

@en

P2093

Axel Heidenreich

http://www.w3.org/2001/XMLSchema#string

European Association of Urology

http://www.w3.org/2001/XMLSchema#string

Filiberto Zattoni

http://www.w3.org/2001/XMLSchema#string

Joaquim Bellmunt

http://www.w3.org/2001/XMLSchema#string

Malcolm Mason

http://www.w3.org/2001/XMLSchema#string

Michel Bolla

http://www.w3.org/2001/XMLSchema#string

Nicolas Mottet

http://www.w3.org/2001/XMLSchema#string

Patrick J Bastian

http://www.w3.org/2001/XMLSchema#string

Thomas Wiegel

http://www.w3.org/2001/XMLSchema#string

Vsevolod Matveev

http://www.w3.org/2001/XMLSchema#string

P304

467-479

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.EURURO.2013.11.002

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

65

http://www.w3.org/2001/XMLSchema#string

P50

Theodorus H Van der Kwast

P577

2013-11-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24321502

http://www.w3.org/2001/XMLSchema#string